COPD combo inhaler therapies compared: LAMA-LABA vs. ICS-LABA

In a propensity score-matched cohort study involving more than 60,000 COPD patients, LAMA-LABA use was associated with an 8% lower rate of first COPD exacerbation and a 20% lower rate of first pneumonia hospitalization, compared with ICS-LABA use. Authors conclude that LAMA-LABA therapy should be preferred for patients with COPD.